{"id":6746,"date":"2024-12-04T16:30:59","date_gmt":"2024-12-04T15:30:59","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?p=6746"},"modified":"2025-05-28T11:20:32","modified_gmt":"2025-05-28T09:20:32","slug":"cdac-platform-moa","status":"publish","type":"post","link":"https:\/\/beonemedaffairs.com\/us\/6746\/cdac-platform-moa\/","title":{"rendered":"CDAC Platform MoA"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"editor_notices":[],"footnotes":""},"categories":[5],"post-tag":[686,613,629,691,690],"specialisation":[],"class_list":["post-6746","post","type-post","status-publish","format-standard","hentry","category-video","post-tag-bgb-16673","post-tag-brutons-tyrosine-kinase","post-tag-btk","post-tag-cdac","post-tag-chimeric-degradation-activation-compound"],"acf":{"visible_for_guests":false,"title":"CDAC Platform MoA","card_title":"CDAC Platform MoA","title_for_guests":"","summary":"Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.","card_summary":"Watch this video to understand the mode of action of Chimeric Degradation Activating Compounds (CDAC), a new investigational targeted approach for hematologic malignancies.","summary_for_guests":"","show_popup_window_to_guests":true,"blur_thumbnail_for_guests":false,"text_app":"","text":"","content-type":5,"download_file_reading":null,"display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"df967373-4e78-4b35-a537-755d331af3a2","motionposter":false,"webcast":"","videolange":"22:02:21","fliphtml_link":"","authors":"","specialisation":[],"tags":[629,613,686,691,690],"visible_tags":[686,691,629],"post_image":7225,"post_image_for_guests":"","related_posts":[{"id":6756,"title":"Zanubrutinib Molecule Overview","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":7219,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/6756\/zanubrutinib-molecule-overview\/","date":"2024-12-04T16:35:14","date_gmt":"2024-12-04T15:35:14"},{"id":6751,"title":"BGB-16673 Molecule Overview","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":7222,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/6751\/bgb-16673-molecule-overview\/","date":"2024-12-04T16:32:27","date_gmt":"2024-12-04T15:32:27"},{"id":6749,"title":"BGB-16673 MoA","title_guest":"","summary":"BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. Watch the mechanism of action video (MoA) to learn more.","summary_guest":"","content-type":5,"post_image":7224,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":"22:02:57","url":"https:\/\/beonemedaffairs.com\/us\/6749\/bgb-16673-moa\/","date":"2024-12-04T16:31:45","date_gmt":"2024-12-04T15:31:45"},{"id":6744,"title":"BTKi Resistance Infographic","title_guest":"","summary":"View this interactive infographic to learn more about acquired BTK mutations that can result in drug resistance.","summary_guest":"","content-type":4,"post_image":7228,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/6744\/btki-resistance-infographic\/","date":"2024-12-04T16:30:24","date_gmt":"2024-12-04T15:30:24"},{"id":6736,"title":"Quick Reference Guide for Hematological Malignancies","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":6737,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/6736\/quick-reference-guide-for-hematological-malignancies\/","date":"2024-12-04T16:27:24","date_gmt":"2024-12-04T15:27:24"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/comments?post=6746"}],"version-history":[{"count":6,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6746\/revisions"}],"predecessor-version":[{"id":7240,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/6746\/revisions\/7240"}],"acf:term":[{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/613"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"category","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories\/5"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories?post=6746"},{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6746"},{"taxonomy":"specialisation","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/specialisation?post=6746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}